MTOR and esophageal squamous cell carcinoma: Aberrant activation of the mTOR pathway has been identified in ESCC, and mTOR specific inhibitors, like everolimus, rapamycin and PP242, exert therapeutic effects both as a single agent and in combination with cisplatin [19, 21, 22, 25].